These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6469433)

  • 1. Clinical pharmacological studies with the vasodilator endralazine in normotensive subjects and essential hypertensives.
    Elliott HL; Meredith PA; Howden CW; Lawrie CB; Reid JL
    Int J Clin Pharmacol Res; 1984; 4(1):61-9. PubMed ID: 6469433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine.
    Elliott HL; Meredith PA; Reid JL
    J Hypertens Suppl; 1984 Dec; 2(3):S551-4. PubMed ID: 6599716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects.
    Meredith PA; Elliott HL; McSharry DR; Kelman AW; Reid JL
    Br J Clin Pharmacol; 1983 Jul; 16(1):27-32. PubMed ID: 6882620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the vasodilator endralazine given with the antihypertensive agent guanfacine on heart rate and blood pressure of spontaneously hypertensive rats and normotensive dogs.
    Salzmann R; Gerber W; Pally C; Scholtysik G
    J Pharm Pharmacol; 1983 May; 35(5):293-8. PubMed ID: 6134797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of endralazine (BO22708), a new vasodilator, in essential hypertension.
    Elliott HL; McLean K; Sumner DJ; Donnelly RJ; Reid JL
    Clin Exp Hypertens A; 1982; 4(8):1409-18. PubMed ID: 6749347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of once daily endralazine in hypertension.
    Wu R; Spence JD; Carruthers SG
    Eur J Clin Pharmacol; 1986; 30(5):553-7. PubMed ID: 3758143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine.
    Kindler J; Rüegg PC; Neuray M; Pacha W
    Eur J Clin Pharmacol; 1987; 32(4):367-72. PubMed ID: 3609114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endralazine, a new peripheral vasodilator--a randomized cross-over trial against dihydralazine.
    Kirch W; Axthelm T
    J Cardiovasc Pharmacol; 1982; 4(4):562-6. PubMed ID: 6181329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of treatment-resistant hypertension: comparison of the antihypertensive effect of endralazine and minoxidil (author's transl)].
    Kindler J; Glöckner WM; Sieberth HG; Konrads A; Meurer KA; Schulz V; Vaith P
    Dtsch Med Wochenschr; 1981 Sep; 106(37):1176-81. PubMed ID: 7343274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antihypertensive pharmacotherapy with the vasodilators captopril and endralazine].
    Hartmann HG; Schumacher H
    Schweiz Med Wochenschr; 1985 Jul; 115(27-28):939-44. PubMed ID: 2862703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
    de Champlain J; Karas M; Nguyen P; Cartier P; Wistaff R; Toal CB; Nadeau R; Larochelle P
    J Hypertens; 1998 Nov; 16(11):1357-69. PubMed ID: 9856375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute haemodynamic effects of endralazine in patients with coronary artery disease and stable angina pectoris.
    van der Wall EE; de Feyter PJ; Res JC; Roos JP; van Engelen CL
    Postgrad Med J; 1983; 59 Suppl 3():42-4. PubMed ID: 6647210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute hemodynamic effects of endralazine: a new vasodilator for chronic refractory congestive heart failure.
    Quyyumi AA; Wagstaff D; Evans TR
    Am J Cardiol; 1983 May; 51(8):1353-7. PubMed ID: 6846162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
    de Champlain J; Karas M; Nguyen P; Cartier P; Wistaff R; Toal CB; Nadeau R; Larochelle P
    J Hypertens; 1998 Sep; 16(9):1357-69. PubMed ID: 9746123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.
    Bogers WA; Meems L
    Eur J Clin Pharmacol; 1983; 24(3):301-5. PubMed ID: 6861845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the in vivo and in vitro cardiovascular effects of a hydralazine-like vasodilator agent (HPS-10) in normotensive rats.
    Orallo F
    Br J Pharmacol; 1997 Aug; 121(8):1627-36. PubMed ID: 9283696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacological studies with the vasodilator endralazine in patients with renal impairment.
    Elliott HL; Meredith PA; Sloan L; Reid JL
    Eur J Clin Pharmacol; 1984; 27(2):159-63. PubMed ID: 6499896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute hypotensive, hemodynamic effects of long-term treatment with niludipine, a Ca2+-antagonist, in patients with essential hypertension. Niludipine monotherapy and combination with a beta-blocker and a diuretic).
    Aoki K; Sato K
    Arzneimittelforschung; 1982; 32(9):1141-5. PubMed ID: 6756418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect.
    Holmes DG; Bogers WA; Wideroe TE; Huunan-Seppala A; Wideroe B
    Lancet; 1983 Mar; 1(8326 Pt 1):670-1. PubMed ID: 6132036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.